TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8733742

Group type: EXPERIMENTAL
Intervention: Increased SPL activation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased difficulty in information processing
Number of subjects: 16
Study: 1770152

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose: 5.0 ± 2.3 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Propranolol (mean daily dose: 182.0 ± 60.5 mg)
Number of subjects: 29
Study: 6755764

Group type: EXPERIMENTAL
Intervention: Intravenous penbutolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31791303

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation in addition to routine inpatient care for 6 months after discharge.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine inpatient care without psychosocial stimulation and home-based follow up for 6 months after discharge.
Number of subjects: 144
Study: 28698319

Group type: EXPERIMENTAL
Intervention: sPATH intervention (five postdischarge motivational interviewing sessions, face to face or by phone)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 290
Study: 26407893

Group type: EXPERIMENTAL
Intervention: Self-report questionnaire assessing self-sufficiency
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Self-Sufficiency Matrix for professionals (SSM-D)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Self-report questionnaire and SSM-D combined
Number of subjects: 581
Study: 23558545

Group type: EXPERIMENTAL
Intervention: Model-free reinforcement-learning strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model-based reinforcement-learning system
Number of subjects: 0
Study: 21667366

Group type: EXPERIMENTAL
Intervention: Threat plus genetic prime message
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard threat message
Number of subjects: 125

Group type: COMPARATOR
Intervention: Self-identified racial/ethnic minority groups
Number of subjects: 125

Group type: COMPARATOR
Intervention: Self-identified Caucasian smokers
Number of subjects: 125
Study: 19524895

Group type: EXPERIMENTAL
Intervention: Laparoscopic oophorectomy, ovarian tissue cryopreservation, and in vitro maturation of primary oocytes
Number of subjects: 1
Study: 17023203

Group type: EXPERIMENTAL
Intervention: 4 g ascorbic acid daily for 4 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15010185

Group type: EXPERIMENTAL
Intervention: High energy density (HED) foods
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low energy density (LED) foods
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Food unit size (small food unit (SFU) or customary food unit (CFU))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All treatments (HED and LED with SFU and CFU)
Number of subjects: 20
Study: 11236112

Group type: EXPERIMENTAL
Intervention: Atosiban (n = 363; intravenous (iv) bolus dose of 6.75 mg, then 300 microg/minute iv for 3h and 100 microg/min iv thereafter)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Beta-agonists (n = 379; ritodrine, salbutamol or terbutaline iv; dose titrated)
Number of subjects: 742
Study: 9661687

Group type: EXPERIMENTAL
Intervention: C1 inhibitor concentrate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 36
Study: 7917371

Group type: EXPERIMENTAL
Intervention: Radical mastectomy and radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mastectomy only
Number of subjects: 0
Study: 2511744

Group type: EXPERIMENTAL
Intervention: Flecainide treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 81
Study: 4948416

Group type: EXPERIMENTAL
Intervention: Tetracycline, 2 doses daily for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (multivitamins)
Number of subjects: 0
Study: 29520816

Group type: EXPERIMENTAL
Intervention: Self-assembling peptide matrix (SAPM) gel, applied ex-office over 1 week
Number of subjects: 50

Group type: COMPARATOR
Intervention: 8% arginine and calcium carbonate (ACC) toothpaste, applied ex-office over 90 days
Number of subjects: 50
Study: 26258927

Group type: EXPERIMENTAL
Intervention: Telehealth service delivery model with combined pharmacotherapy and behavior training
Number of subjects: 223

Group type: COMPARATOR
Intervention: Management in primary care augmented with a telepsychiatry consultation
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Telepsychiatrists' decision making regarding medication adjustments
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Telepsychiatrists' fidelity to chosen algorithms in medication management
Number of subjects: 223
Study: 24898318

Group type: EXPERIMENTAL
Intervention: Equine facilitated learning (EFL) program, 11 weeks, once-weekly 90-min sessions
Number of subjects: 131

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 131
Study: 22907186

Group type: EXPERIMENTAL
Intervention: Microfat grafts with adipose-derived stem cells (ASCs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Microfat grafts alone
Number of subjects: 10
Study: 20616418

Group type: COMPARATOR
Intervention: Triple therapy (TT) comprising clarithromycin, amoxicillin, omeprazole [n=23]
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 1 g Nigella sativa + 40 mg omeprazole [n=21]
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 2 g Nigella sativa + omeprazole [n=21]
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 3 g Nigella sativa + omeprazole [n=23]
Number of subjects: 88
Study: 18520829

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications (specific combinations include timolol + dorzolamide, timolol + dorzolamide + pilocarpine)
Number of subjects: 378

Group type: COMPARATOR
Intervention: No glaucoma (control group)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications (timolol + dorzolamide)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications (timolol + dorzolamide + pilocarpine)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 378
Study: 15784718

Group type: EXPERIMENTAL
Intervention: Low GH dose (0.033 mg/kg.d or 0.1 IU/kg.d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High GH dose (0.067 mg/kg.d or 0.2 IU/kg.d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH (both low and high doses)
Number of subjects: 30
Study: 12964289

Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 35
Study: 9387137

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 23
Study: 7955757

Group type: EXPERIMENTAL
Intervention: Antigranulocyte antibody imaging
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Three-phase bone scans
Number of subjects: 37
Study: 3671899

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/8 h) for 3 days prior to ascent and continued for 15 days at altitude
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2767500

Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 24
Study: 30015697

Group type: EXPERIMENTAL
Intervention: CPAP therapy (40% fraction of inspired oxygen, 8 cm H2O CPAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: COT (classic oxygen therapy via facemask at 6 L/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: COT
Number of subjects: 40
Study: 28880902

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% + Clonidine 150μg/ml
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ropivacaine 0.5% + Saline (Placebo)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ropivacaine + Clonidine
Number of subjects: 21
Study: 25084754

Group type: EXPERIMENTAL
Intervention: State-anxiety induction
Number of subjects: 122

Group type: COMPARATOR
Intervention: No state-anxiety induction (Control)
Number of subjects: 122
Study: 23239151

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg + pazopanib 800 mg (Cohort 1)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Lapatinib 1,500 mg (Cohort 1)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Lapatinib 1,500 mg (Cohort 2)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,000 mg + pazopanib 400 mg (Cohort 2)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg (Cohort 2)
Number of subjects: 164
Study: 21605022

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 51
Study: 19212164

Group type: EXPERIMENTAL
Intervention: TransWarmer Infant Transport Mattress
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 115
Study: 16706613

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) treatment for 48 weeks
Number of subjects: 627

Group type: COMPARATOR
Intervention: Baseline susceptibility to enfuvirtide
Number of subjects: 627

Group type: COMPARATOR
Intervention: Baseline coreceptor tropism and viral subtype
Number of subjects: 627
Study: 15841624

Group type: EXPERIMENTAL
Intervention: Myobloc (5,000 U per palm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1.0 mL vehicle)
Number of subjects: 20
Study: 11605178

Group type: EXPERIMENTAL
Intervention: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 6) on day 1 every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 2) weekly for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel 150 mg/m(2)/wk + carboplatin (AUC 2 per week) during the second 8-week cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance weekly paclitaxel after initial treatment
Number of subjects: 0
Study: 9663369

Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.15 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.3 mg and 0.15 mg of cerivastatin sodium combined
Number of subjects: 73
Study: 7839953

Group type: EXPERIMENTAL
Intervention: 1 or 5 or 10 tuberculin units of Tween‐80 stabilised purified protein derivative (P.P.D.)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (volunteers)
Number of subjects: 112
Study: 3342919

Group type: EXPERIMENTAL
Intervention: Prevention campaign in treated departments
Number of subjects: 0

Group type: COMPARATOR
Intervention: No actions in control departments
Number of subjects: 0
Study: 31735328

Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 1905

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Discharge RHR (continuous variable per 5 bpm)
Number of subjects: 1905
Study: 30624150

Group type: EXPERIMENTAL
Intervention: CP@clinic intervention (community-based, paramedic-led program for one year)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CP@clinic intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 30
Study: 29390528

Group type: EXPERIMENTAL
Intervention: Minocycline plus PDT (n=48)
Number of subjects: 95
Study: 26232120

Group type: EXPERIMENTAL
Intervention: Autogenous bone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Autogenous bone + β‐TCP
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: β‐TCP alone
Number of subjects: 32
Study: 23808581

Group type: EXPERIMENTAL
Intervention: Prolonged conservative care protocol
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Utility scores from 8 weeks
Number of subjects: 93
Study: 21350425

Group type: EXPERIMENTAL
Intervention: Pantogam activ (1800 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pantogam activ
Number of subjects: 40
Study: 19691566

Group type: EXPERIMENTAL
Intervention: hIVIG
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: hIVIG and glucocorticoids
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo and glucocorticoids
Number of subjects: 28
Study: 17024947

Group type: EXPERIMENTAL
Intervention: Group 1 specimens coated with resin and light cured for 10 seconds
Number of subjects: 16

Group type: COMPARATOR
Intervention: Group 2 specimens left uncoated
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 16
Study: 12764909

Group type: EXPERIMENTAL
Intervention: Yishou Tiaozhi Tablet (YSTZT) 4 tablets 3 times a day for 60 days
Number of subjects: 168

Group type: COMPARATOR
Intervention: Zocor 1 tablet before sleep every evening for 60 days
Number of subjects: 168
Study: 11421893

Group type: EXPERIMENTAL
Intervention: Active treatment (grass pollen-specific allergy vaccine with MPL adjuvant)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (tyrosine alone)
Number of subjects: 81
Study: 9240319

Group type: EXPERIMENTAL
Intervention: Azathioprine (1 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no azathioprine)
Number of subjects: 40
Study: 7506322

Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg o.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Metoprolol (100-200 mg o.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of Metoprolol (acute treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of Carvedilol (acute treatment)
Number of subjects: 12
Study: 3300250

Group type: EXPERIMENTAL
Intervention: Amino acid dialysates (1.1% and 2.0%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose dialysates (2.5% and 4.25%)
Number of subjects: 0
Study: 31733336

Group type: EXPERIMENTAL
Intervention: Twice-daily soak-and-seal (SS) baths for 15 to 20 minutes (wet method)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Twice-daily soak-and-seal (SS) baths (wet method)
Number of subjects: 42
Study: 30326947

Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy (3 MHz, 0.132 W/cm2, 1.3 W) applied daily for 4 hours over 6 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy (in pilot subset)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment (in pilot subset)
Number of subjects: 90
Study: 27517053

Group type: EXPERIMENTAL
Intervention: ArmeoSpring training for 45 minutes daily, 5 days per week for 3 weeks, in addition to conventional rehabilitation
Number of subjects: 48
Study: 23872080

Group type: EXPERIMENTAL
Intervention: Staff-supported group (n=69)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Self-guided group (n=59)
Number of subjects: 128
Study: 22218156

Group type: COMPARATOR
Intervention: Strength training only (ST group) for 90 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength training with fish oil supplementation (ST90 group) for 90 days (2 g/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength training with fish oil supplementation (ST150 group) for 150 days (2 g/d, supplemented 60 days before training)
Number of subjects: 45
Study: 20932341

Group type: EXPERIMENTAL
Intervention: Intra-articular BMP-7 (1 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intra-articular BMP-7 (0.1 mg and 0.3 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: OARSI responder criteria (BMP-7 groups)
Number of subjects: 33

Group type: COMPARATOR
Intervention: OARSI responder criteria (Placebo)
Number of subjects: 33
Study: 17660078

Group type: EXPERIMENTAL
Intervention: Group II (n=13) trained on the FLS videotrainer model until a proficiency score of 512 was achieved.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group III (n=13) trained under constrained conditions to the same proficiency goal.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Group I (n=6) received no training.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group III trained longer (329+/‐71 minutes) and performed more repetitions (81+/‐15) than group II (239+/‐69 minutes and 59+/‐14 repetitions).
Number of subjects: 32
Study: 15663444

Group type: EXPERIMENTAL
Intervention: Flowable restorative system (Bond 1 + Flow‐It!)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional filled resin sealant (Fluroshield)
Number of subjects: 40
Study: 11859235

Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion with acute normovolemic hemodilution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group receiving autotransfusion alone
Number of subjects: 80
Study: 10435217

Group type: EXPERIMENTAL
Intervention: Comprehensive multicomponent school and community intervention
Number of subjects: 0
Study: 8592597

Group type: EXPERIMENTAL
Intervention: 5 mg/kg DFO test
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 10 mg/kg DFO test
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 5 mg/kg DFO test for detecting aluminium toxicity
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 10 mg/kg DFO test for detecting aluminium toxicity
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 5 mg/kg DFO test for detecting aluminium overload
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 10 mg/kg DFO test for detecting aluminium overload
Number of subjects: 77
Study: 1978481

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 18
Study: 336257

Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 36

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 36
Study: 30611752

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg/kg of body-mass)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28132795

Group type: EXPERIMENTAL
Intervention: Standardized Field Sobriety Test (SFST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hack's Impairment Index (HII)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: St. Elizabeth Alcohol Intoxication Scale (STE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binary Intoxication Question (BIQ)
Number of subjects: 0
Study: 26919081

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide in-office bleaching
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20% hydrogen peroxide in-office bleaching
Number of subjects: 30
Study: 24252360

Group type: EXPERIMENTAL
Intervention: Olaparib, 400 mg orally twice daily until disease progression or drug intolerance
Number of subjects: 12
Study: 22999717

Group type: EXPERIMENTAL
Intervention: E‐ZES+3‐month DAPT, n=1059
Number of subjects: 2117

Group type: COMPARATOR
Intervention: Standard therapy (12‐month DAPT), n=1058
Number of subjects: 2117
Study: 20220747

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sirolimus
Number of subjects: 0
Study: 17978849

Group type: EXPERIMENTAL
Intervention: Nonsterile gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Povidine-iodine
Number of subjects: 60
Study: 15901604

Group type: EXPERIMENTAL
Intervention: Alternative assessment (data collection by a respiratory therapist with repeat assessment after 2 months of stability)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Conventional assessment (data collected by oxygen providers and judgments by Home Oxygen Program personnel)
Number of subjects: 546
Study: 12407043

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 50 mg on days 2-6
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg on days 5-9
Number of subjects: 35
Study: 10428533

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study: 8532497

Group type: EXPERIMENTAL
Intervention: Attentionally highlighted event structure with accents coinciding with grammatical phrase boundaries (Experiment 1 and 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obscured event structure with accents conflicting with grammatical phrase boundaries (Experiment 1 and 2)
Number of subjects: 0
Study: 1730330

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) deslorelin, 300 micrograms daily for 4 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6699892

Group type: EXPERIMENTAL
Intervention: Tutored videotape-instruction (TVI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live lectures
Number of subjects: 0
Study: 31525148

Group type: EXPERIMENTAL
Intervention: Who Do You Tell?™ child sexual abuse education program
Number of subjects: 6198
Study: 29768149

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed
Number of subjects: 3849

Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg) used as needed
Number of subjects: 3849

Group type: COMPARATOR
Intervention: Budesonide (200 μg) plus terbutaline used as needed
Number of subjects: 3849
Study: 26704966

Group type: EXPERIMENTAL
Intervention: Thickened extensively casein hydrolyzed protein formula (T-eCHF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Non-thickened extensively casein hydrolyzed protein formula (NT-eCHF)
Number of subjects: 71
Study: 23171140

Group type: EXPERIMENTAL
Intervention: Laparoscopic trainer box warm-up
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PlayStation 2 warm-up
Number of subjects: 109

Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 109
Study: 24140183

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg per day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 21129474

Group type: EXPERIMENTAL
Intervention: Topical Tangzu Yuyang Ointment (TYO) plus standard wound therapy (SWT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard wound therapy (SWT)
Number of subjects: 57
Study: 20467528

Group type: EXPERIMENTAL
Intervention: Home walking program (30 min, 3 times a week for 12 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (refrained from any regular exercise)
Number of subjects: 12